Cargando…

Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study

A triple negative breast cancer model using the murine 4T1 tumor cell line was used to explore the efficacy of an adjuvanted survivin peptide microparticle vaccine using tumor growth as the outcome metric. We first performed tumor cell dose titration studies to determine a tumor cell dose that resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burkholz, Scott R., Herst, Charles V., Carback, Richard T., Harris, Paul E., Rubsamen, Reid M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051918/ https://www.ncbi.nlm.nih.gov/pubmed/36992227 http://dx.doi.org/10.3390/vaccines11030644

Ejemplares similares

Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome
por: Rubsamen, Reid, et al.
Publicado: (2020)

Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications
por: Wright, Sharon, et al.
Publicado: (2023)

Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and back to humans
por: Burkholz, Scott, et al.
Publicado: (2021)

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
por: Harris, Paul E., et al.
Publicado: (2021)

Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron
por: Burkholz, Scott, et al.
Publicado: (2023)

An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
por: Herst, C.V., et al.
Publicado: (2020)

BIRC5/Survivin Expression as a Non-Invasive Biomarker of Endometriosis
por: Filipchiuk, Carolina, et al.
Publicado: (2020)

Polymorphisms in Survivin (BIRC5 Gene) Are Associated with Age of Onset in Breast Cancer Patients
por: Sušac, Ilona, et al.
Publicado: (2019)

The BIRC Family Genes Expression in Patients with Triple Negative Breast Cancer
por: Makuch-Kocka, Anna, et al.
Publicado: (2021)

Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells
por: Conde, Marina, et al.
Publicado: (2017)

Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma
por: Troiano, Giuseppe, et al.
Publicado: (2018)

Genetic polymorphisms and epigenetic regulation of survivin encoding gene, BIRC5, in multiple sclerosis patients
por: Rahban, Dariush, et al.
Publicado: (2019)

Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts
por: Oparina, Nina, et al.
Publicado: (2021)

Survivin (BIRC5) regulates bladder fibrosis in a rat model of partial bladder outlet obstruction
por: Di, Xingpeng, et al.
Publicado: (2023)

The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer
por: Adinew, Getinet M., et al.
Publicado: (2022)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
por: Frazzi, Raffaele
Publicado: (2021)

Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors
por: Brandi, Andressa, et al.
Publicado: (2022)

Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
por: Li, Fengzhi, et al.
Publicado: (2019)

Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors
por: Jugel, Willi, et al.
Publicado: (2021)

Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model
por: Garg, Himani, et al.
Publicado: (2018)

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
por: Gandhi, Shipra
Publicado: (2023)

Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma
por: Zoon, Christine K., et al.
Publicado: (2017)

Differential regulation of BIRC2 and BIRC3 expression by inflammatory cytokines and glucocorticoids in pulmonary epithelial cells
por: Thorne, Andrew, et al.
Publicado: (2023)

An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling
por: Cunha-Neto, Edecio, et al.
Publicado: (2017)

The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting BIRC5 to Elucidate the Synergistic Pathway of Survivin with P-Glycoprotein in Cancer Multi-Drug Resistance
por: Deng, Changping, et al.
Publicado: (2022)

Surface plasmon resonance immunosensor for label-free detection of BIRC5 biomarker in spontaneously occurring canine mammary tumours
por: Jena, Subas Chandra, et al.
Publicado: (2019)

Overexpression of BIRC6 driven by EGF-JNK-HECTD1 signaling is a potential therapeutic target for triple-negative breast cancer
por: Li, Yongpeng, et al.
Publicado: (2021)

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
por: Lei, Josh Haipeng, et al.
Publicado: (2021)

Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential
por: Yamato, Azusa, et al.
Publicado: (2015)

Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: A case report
por: Zhao, Xiangwang, et al.
Publicado: (2023)

Increased Expression of BIRC2, BIRC3, and BIRC5 from the IAP Family in Mesenchymal Stem Cells of the Umbilical Cord Wharton's Jelly (WJSC) in Younger Women Giving Birth Naturally
por: Gil-Kulik, Paulina, et al.
Publicado: (2020)

Deptor Enhances Triple-Negative Breast Cancer Metastasis and Chemoresistance through Coupling to Survivin Expression()()
por: Parvani, Jenny G., et al.
Publicado: (2015)

MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells
por: Wang, Chen, et al.
Publicado: (2012)

BIRC5/Survivin is a novel ATG12–ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells
por: Lin, Tzu-Yu, et al.
Publicado: (2019)

Bioinformatics analysis of BIRC5 in human cancers
por: Ye, Han-Bin, et al.
Publicado: (2022)

Gene Network Revealed Involvements of Birc2, Birc3 and Tnfrsf1a in Anti-Apoptosis of Injured Peripheral Nerves
por: Wang, Yongjun, et al.
Publicado: (2012)

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
por: Garufi, Giovanna, et al.
Publicado: (2022)

Significance of combined TGF-β1 and survivin expression on the prognosis of patients with triple-negative breast cancer
por: Liu, Nannan, et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l3afl42avacu2net7r5ahdh62c